Daniel L. Menichella
Director/Board Member bei Spybiotech Ltd.
Profil
Daniel L.
Menichella currently works at Spybiotech Ltd., as Director.
Mr. Menichella also formerly worked at CureVac SE, as Chief Executive Officer from 2018 to 2020, Kaleido Biosciences, Inc., as President, Chief Executive Officer & Director from 2020 to 2022, Paloma Pharmaceuticals, Inc., as Director, Merck KGaA, as Vice President-Business Development from 2002 to 2007, Zyngenia, Inc., as Chief Business Officer, MorphoSys AG, as Senior Vice President, Grifols Therapeutics, Inc., as Senior Vice President-Business Development from 2007 to 2011, Beacon Therapeutics (USA), Inc., as Chief Business Officer & Vice President from 2013 to 2015, Talecris Biotherapeutics Holdings Corp., as Senior Vice President-Business Development from 2007 to 2011, and Bamboo Therapeutics, Inc., as Chief Business Officer.
Mr. Menichella received his undergraduate degree from Harvard University and Masters Business Admin degree from The University of North Carolina at Charlotte.
Aktive Positionen von Daniel L. Menichella
| Unternehmen | Position | Beginn |
|---|---|---|
Spybiotech Ltd.
 Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | Director/Board Member | - |
Ehemalige bekannte Positionen von Daniel L. Menichella
| Unternehmen | Position | Ende |
|---|---|---|
| KALEIDO BIOSCIENCES, INC. | Chief Executive Officer | 08.04.2022 |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Chief Executive Officer | 11.03.2020 |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 28.01.2015 |
Zyngenia, Inc.
 Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Grifols Therapeutics, Inc.
 Grifols Therapeutics, Inc. BiotechnologyHealth Technology Grifols Therapeutics, Inc. specialized in the pharmaceutical-hospital services. The company was founded on March 7, 2005 and is headquartered in Research Triangle Park, NC. | Corporate Officer/Principal | 01.09.2011 |
Ausbildung von Daniel L. Menichella
| Harvard University | Undergraduate Degree |
| The University of North Carolina at Charlotte | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MERCK KGAA | Health Technology |
| MORPHOSYS AG | Health Technology |
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Paloma Pharmaceuticals, Inc.
 Paloma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Paloma Pharmaceuticals, Inc. manufactures pharmaceutical drugs and related products. The firm’s product Cialis which develops drugs for cancer, ocular diseases, arthritis, fibrotic diseases, antiviral, skin diseases and erectile dysfunction. The company is headquartered in Jamaica Plain, MA. | Health Technology |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Zyngenia, Inc.
Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Retail Trade |
Grifols Therapeutics, Inc.
Grifols Therapeutics, Inc. BiotechnologyHealth Technology Grifols Therapeutics, Inc. specialized in the pharmaceutical-hospital services. The company was founded on March 7, 2005 and is headquartered in Research Triangle Park, NC. | Health Technology |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Talecris Biotherapeutics Holdings Corp.
 Talecris Biotherapeutics Holdings Corp. BiotechnologyHealth Technology Talecris Biotherapeutics Holdings Corp. develops and markets plasma-derived protein therapy products. The company was founded in 1942 and is headquartered in Research Triangle Park, NC. | Health Technology |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | Health Technology |
